Consensus $20.98. Raises FY24 revenue view to $69.75B-$71.75B from $67.75B-$70.25B, consensus $69.79B. Sees FY24 capital expenditures $5.1B-$5.3B. The company said, “The Company’s revised 2024 guidance contains a number of assumptions, including, among others, the Company’s current expectations regarding patient volumes and payor mix as well as general economic conditions, including inflation, and excludes the impact of items such as, but not limited to, gains or losses on sales of facilities, losses on retirement of debt, legal claims costs and impairment of long-lived assets.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCA:
- HCA Earnings this Week: How Will it Perform?
- HCA Healthcare price target raised to $362 from $317 at Bernstein
- HCA Healthcare price target raised to $376 from $367 at Barclays
- HCA Healthcare price target raised to $375 from $359 at Deutsche Bank
- Augmedix says Go ED has met HCA’s criteria for expansion